Cancer Genetics' IPO delayed amid Facebook frenzy

Cancer Genetics has nixed plans to launch an initial public offering this week, having planned to raise $48 million to advance a pipeline of molecular diagnostics for cancer, Renaissance Capital reported Thursday. Last week Rib-X Pharmaceuticals delayed its own IPO, following a history of biotechs struggling to trade their shares on the public market. Seeking Alpha reasoned this week that Cancer Genetics' IPO might be small enough to slip through even though Wall Street has been bracing for the blockbuster maiden offering of Facebook. Guess not. Item

 

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.